Hydrogen sulfide: A worthwhile tool in the design of new multitarget drugs by Sestito, Simona et al.
PERSPECTIVE
published: 27 September 2017
doi: 10.3389/fchem.2017.00072
Frontiers in Chemistry | www.frontiersin.org 1 September 2017 | Volume 5 | Article 72
Edited by:
Antonio Randazzo,
University of Naples Federico II, Italy
Reviewed by:
Alla B. Salmina,
Krasnoyarsk State Medical University








This article was submitted to
Medicinal and Pharmaceutical
Chemistry,
a section of the journal
Frontiers in Chemistry
Received: 12 August 2017
Accepted: 15 September 2017
Published: 27 September 2017
Citation:
Sestito S, Nesi G, Pi R, Macchia M
and Rapposelli S (2017) Hydrogen
Sulfide: A Worthwhile Tool in the
Design of New Multitarget Drugs.
Front. Chem. 5:72.
doi: 10.3389/fchem.2017.00072
Hydrogen Sulfide: A Worthwhile Tool
in the Design of New Multitarget
Drugs
Simona Sestito 1, Giulia Nesi 1, Rongbiao Pi 2, 3, 4, Marco Macchia 1 and Simona Rapposelli 1*
1Department of Pharmacy, University of Pisa, Pisa, Italy, 2 School of Pharmaceutical Sciences, Sun Yat-Sen University,
Guangzhou, China, 3 International Joint Laboratory (SYSU-PolyU HK) of Novel Anti-Dementia Drugs of Guangdong,
Guangzhou, China, 4Guangdong Province Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine,
Sun Yat-sen University, Guangzhou, China
H2S is a gaseous molecule able to trigger a plethora of central physiological
and pharmacological effects as antioxidant, pro- and anti-inflammatory, pro- and
anti-nociceptive, neuromodulator, and cytoprotective. The polypharmacology of H2S
depends on the wide variety of targets implicated, but, despite the efforts, the
mechanisms of action that should clarify its activity are still not completely unrevealed.
Nevertheless, many attempts to exploit the multifaceted profile of this molecule have
already been accomplished and many chemical entities containing an H2S-releasing
pharmacophore have been synthetized. Here we discuss recent investigations on
multitarget molecules able to release H2S, with a particular focus on the combinations
of “native drug” with moieties structurally able to release H2S and their applications
as therapeutic tools in bone disease, gastrointestinal system and neurodegenerative
disorders.
Keywords: hydrogen sulfide, multitarget-directed ligands, bone disease, hybrid molecules, H2S-donors,
multifunctional compounds, antioxidants, neurodegenerative disorders
INTRODUCTION
Nitric oxide (NO), carbonmonoxide (CO) andmore recently hydrogen sulfide (H2S) have emerged
as “gasotransmitters” with central physiological and pharmacological effects. In the past three
decades, NO has been widely investigated for its role in controlling blood circulation and regulating
activities of the brain, lungs, liver, kidneys, stomach and other organs (Marsh and Marsh, 2000).
More recently, H2S, another “toxic gas,” also appeared as important regulatory mediator (Moore
et al., 2003).
H2S and NO exhibit many common traits like the ability to cross the biological membranes and
to penetrate cells without the need of specific membrane receptors. Moreover, these molecules have
been involved in the induction of hippocampal long-term potentiation, thus suggesting a key role
as neuromodulators in the brain (Qu et al., 2008). Additionally, both mediators are well-known for
their capability to regulate the blood pressure both in vitro and in vivo (Ali et al., 2006).
H2S plays the same multiple protective roles in the vascular system exhibited by NO but, in
contrast to this latter, H2S is not associated with the harmful production of reactive oxygen species
(ROS) (Whiteman et al., 2004). Probably H2S protects against cellular damage through an up-
regulation of the nuclear-factor-E2-related factor-2 (Nrf2)-dependent signaling pathway (Calvert
et al., 2009, Figure 1).
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In mammals, enzymatic H2S biosynthesis originates
primarily from cysteine and homocysteine metabolism due
to cystathionine-γ-lyase (CSE), cystathionine-β-synthase (CBS),
and 3-mercaptopyruvate sulfurtransferase (3-MST)/cysteine
aminotransferase (CAT) (Kimura, 2010). The expression of these
enzymes is tissue-specific, with CBS being found predominantly
in the brain and nervous system, while CSE is mainly expressed
in the liver and in vascular/non-vascular smooth muscle.
Conversely, 3MST is ubiquitously localized in many systems
such as liver, kidney, heart, lung, thymus, testis, thoracic aorta
and brain (Shibuya et al., 2009a,b).
The rapidly expanding literature related to H2S shows that
this gasotransmitter triggers cardiovascular protection (Sun et al.,
2017b; Wallace et al., 2017), possesses antitumor activity (Ianaro
et al., 2016), regulates ion channels function (Naik et al., 2016; Lu
et al., 2017), and displays antioxidants effects (Egea et al., 2015).
Given these physiological roles, H2S appears to act as a mediator
in several functions, thus representing a potential therapeutic
agent as well as NO and CO.
HYDROGEN SULFIDE AND EFFECTS ON
BONE
Recent studies on physiological and pathophysiological roles of
H2S, revealed its therapeutic potential in bone diseases (Liu et al.,
2014; Zhai et al., 2017).
Osteoporosis is an endemic bone disease of the Western
society characterized by an imbalance between bone resorption
and bone formation. Physiologically, osteoblasts are responsible
for bone formation and osteoclasts are associated with bone
degradation. Although the exact mechanism linking H2S to
FIGURE 1 | Designing smart agents through the combination of H2S pharmacological properties with old drugs.
bone formation is still not clarified, it turned out that this
gasotransmitter inhibits the differentiation of osteoclasts through
a mechanism involving antioxidant response without affecting
cell viability (Gambari et al., 2014). Indeed, the study of Xu et al.
showed that H2S protects osteoblastic MC3T3-E1 cells against
oxidative stress (OS) via inhibition of mitogen-activated protein
kinase (MAPK) signaling (Xu et al., 2011). Interestingly, H2S-
donors such as GYY4137, stimulates osteogenic differentiation
of human mesenchymal stromal cells (h-MSCs) both in vitro
(Grassi et al., 2016) and in vivo (Liu et al., 2014). Consequently,
the dual activity profile of H2S inspired the development
of new molecules based on the multitarget-directed ligands
(MTDLs) approach as alternative strategy to design new potential
treatments for bone diseases.
The traditional Chinese medicine Danshensu, also known
as DSS (3-(3,4-dihydroxyphenyl) lactic acid), is a natural
phenolic acid isolated from Salvia miltiorrhiza root, recognized
for its ability to reduce inflammation and suppress ROS
formation (Lu et al., 2014; Jiang et al., 2015). In a more
recent study, it turned out that DSS protects bone from
glucocorticoids-induced bone marrow impairment through the
stimulation of osteogenesis; moreover, it depresses adipogenesis
in bone marrow stromal cells both in vivo and in vitro (Liao
et al., 2009). These observations prompted Bian to develop
a multifunctional molecule starting from acetyl-DSS and
5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione (ADT-OH), a
well characterized molecule known to release H2S (Yan et al.,
2017). It has been demonstrated that the newly synthesized
hybrid, SDSS (α-3, 4-tris (acetyloxy) benzenepropanoic acid
4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester) (Table 1), after
injection into animals, is quickly deacetylated or de-esterified
generating ADT-OH, an intermediate capable to induce
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TABLE 1 | Structure of MTDL compounds and their in vitro and in vivo H2S-mediated biological effects.
Structure Chemicals name In vitro H2S-mediated effects In vivo H2S-mediated effects
SDSS Protection of osteoblasts from OS n.a.




ACS14 n.a. Preservation of gastric mucosa
integrity
GIC1001 n.a. Reduction of nociceptive
response to all injuries
ITH12674 Induction of neuroprotective antioxidant
properties and enhancement of the
Nrf2–ARE transcriptional response
n.a.
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H2S-release both in vivo and in vitro. The H2S release from SDSS
has been confirmed through a fluorescent probe in MC3T3-E1
cells. The new compound also prevents the reduction of the
alkaline phosphatase activity, the loss of collagen expression, and
the inhibition of bone nodule formation in osteoblasts treated
with H2O2. Moreover, SDSS seems to suppress OS and improve
mitochondrial function in MC3T3-E1 cells, as well as to inhibit
MAPKs and activate the phosphatidylinositol 3-kinase/Akt
pathway (Yan et al., 2017). These results suggest that SDSS may
protect osteoblasts from OS-induced cell injury and stimulate
cell differentiation.
Nowadays, bisphosphonates (BPs) still represent the first-line
and the most prescribed drugs in the treatment of osteoporosis
and in the management of metastatic bone disease. BPs have a
relatively good safety profile and are tolerated by the majority
of patients even though they show several adverse effects
among which: gastrointestinal injury, osteonecrosis of the jaws
(ONJ) and atypical subtrochanteric femoral fractures (Conte and
Guarneri, 2004; Ruggiero, 2011; Kharazmi et al., 2014).
In order to overcome the side effects of BPs, Rapposelli et al.
have recently synthesized an innovative molecule called DM-22
(Table 1), obtained by the combination of alendronate (AL) with
aryl-isothiocyanate moiety as H2S-releasing group (Lisignoli
et al., 2016). Amperometric measurements of H2S generation
from DM-22 showed that the hybrid compound is able to release
H2S in the presence of organic thiols, such as L-cysteine, with
a long-lasting kinetic. Comparing DM-22 with the progenitor
molecule (i.e., AL), a substantially improved profile was observed
in terms of safety and efficacy on human mesenchymal cell
lines (h-MSCs) induced to osteogenic differentiation. Contrary
to AL, this new molecule is also able to induce a nearly 3-
fold increasing in the mRNA expression of Collagen I and
Bone Sialoprotein (BSP) compared to control MSC, thus leading
to bone mineralization. This multitarget compound showed,
in bone cells in vitro, an increase of both anabolic and anti-
resorptive functions compared to the parent drug. In the
light of these findings, DM-22 could represent a prototype of
a novel family of hybrid molecules useful in treating bone
loss.
HYDROGEN SULFIDE AND EFFECTS ON
GASTROINTESTINAL SYSTEM
H2S is closely linked with the gastrointestinal (GI) system and it
is also implicated in its regulation (Bala et al., 2014; Brzozowski
et al., 2017; Souza et al., 2017). Beside the host production, H2S
can be produced exogenously during the digestive processes or
by microbes. Its pro- and anti-inflammatory, smooth muscle
relaxant, pro-secretory, and pro- and anti-nociceptive actions are
well documented in literature, even though its activity is not
clarified as a whole (Linden, 2014).
H2S is involved in the cytoprotection of gastric mucosa;
gastric mucosa is constantly exposed to exogenous substances,
some of which, such as ethanol, nicotine and non-steroidal
anti-inflammatory drugs (NSAIDs), can affect its integrity.
Therefore, the mucosa possesses various protective mechanisms
including the release of gaseous mediators such as NO
and H2S, generally recognized to be implicated in the
maintenance of gastrointestinal integrity and in the mechanism
of gastroduodenal protection (Magierowski et al., 2015).
In this regard, GI ulceration and bleeding associated with the
use of conventional NSAIDs still represent the major issues to
overcome. Considerable efforts have been done in the recent
past to develop innovative anti-inflammatory and analgesic drugs
with minor side effects.
ATB-346 [2-(6-methoxy-napthalen-2-yl)-propionic acid
4-thiocarbamoyl-phenyl ester] (Table 1) is an H2S-releasing
derivative of naproxen (Wallace et al., 2010). Naproxen is
one of the most used NSAIDs, since some evidence suggested
that its use might be associated with fewer cardiovascular side
effects than selective COX-2 inhibitors and other NSAIDs. The
molecule contains a 4-hydroxyphenyl-thioamide (Martelli et al.,
2013), an H2S-releasing moiety used for the first time with this
purpose. Activity of ATB-346 was evaluated in healthy animals,
in several models characterized by impaired mucosal defense
and in a model of gastric ulcer healing. In terms of gastric
injury, ATB-346 showed to be approximately 100-fold safer
than naproxen in healthy animals, exerting also comparable or
superior effects respect to those of naproxen in two models of
inflammation. Additionally, in opposition to selective COX-2
inhibitors, ATB-346 did not produce significant gastric damage
in rats with compromised mucosal defense; it also enhances
healing of pre-existing gastric ulcers. Importantly, ATB-346
exhibited a better cardiovascular profile than conventional
NSAIDs.
Similarly, ACS14 [2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,
2-dithiol-5-yl) phenyl ester] (Table 1) is a H2S releasing
compound derived from the conjunction of acetylsalicylic acid
with ADT-OH (Liu et al., 2012). ACS14 proved to be an effective
and safe molecule, with significant advantages if compared to
the native drug. Kinetic and metabolic experiments have shown
that, after in vivo administration, ACS14 is transformed mostly
by generating salicylic acid and ADTOH, the H2S-donating
moiety. In addition tomaintaining the thromboxane-suppressing
activity, the aspirin-H2S releasing hybrid preserves the gastric
mucosa integrity through the increase of H2S/GSH formation,
thus affecting the redox imbalance processes (Sparatore et al.,
2009). Additionally, a recent study revealed that ACS14 is also
able to protect gastric mucosa against the aspirin induced damage
through the inhibition of OS and a stimulation of local blood
flow, maybe due to the involvement of KATP channels (Sun et al.,
2017a).
As regards the smooth muscle physiology in GI system,
H2S demostrated beneficial effects since H2S is able to inhibit
muscle contraction, via the inhibition of Rho kinase and PKC
activities and stimulation of MLCP activity, which lead to
dephosphorylation of the 20-kDa regulatory light chain of
myosin II (MLC20) (Nalli et al., 2015).
Different studies investigated the effect of H2S on nociception
in GI. Even though endogenous H2S produced by CBS seems
to contribute to visceral hypersensitivity in rats (Xu et al.,
2009), exogenous H2S is able to decrease colorectal distension-
induced nociception via activation of ATP-dependent K+ (KATP)
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channels. Anti-nociceptive effects of H2S seem to involve also an
AKT-dependent transactivation and internalization of µ-opioid
receptors (Distrutti et al., 2010).
These results led to the hypothesis that the combination
of an opioid receptor agonist (such as trimebutine) with an
H2S-releasing moiety could theoretically provide an additive or
even synergistic analgesic effect. Therefore GIC-1001 (Table 1),
a new and improved trimebutine derivative able to release H2S
in vivo, has been developed: this drug is a salt composed of
trimebutine functionalized with the H2S-releasing counter ion
3-thiocarbamoylbenzoate (3TCB) (Cenac et al., 2015). GIC-1001
has been tested in mouse model of colorectal distension. It
showed to significantly reduce, in a dose-dependent manner,
nociceptive response to all injuries; this effect is considerably
improved if compared to equimolar administration of its parent
trimebutine maleate salt. Taking into account the better efficacy
in animal model and the safety for its use in humans (phase
I study completed; ClinicalTrials.gov Identifier: NCT01738425),
GIC-1001 was subjected to phase II study, demonstrating a
clinically significant pain reduction (ClinicalTrials.gov Identifier:
NCT01926444).
Summarizing, the H2S release evoked by GIC-1001
potentiates the µ-opioid receptor agonistic activity of
trimebutine in mouse model. Therefore, the orally administered
drug salt GIC-1001 represents an alternative to i.v. sedation
during full colonoscopy. Moreover, GIC-1001 could also be
potentially useful as a new treatment for the irritable bowel
syndrome (IBS) associated to the visceral hypersensitivity.
To date, further studies are still required to shed light on how
better exploit H2S polyhedral activity at the GI level.
HYDROGEN SULFIDE AND EFFECTS
INDUCED ON CNS
A rapid increase in the knowledge on H2S biological functions
suggests that defects in H2S metabolism may be involved
in CNS diseases (Ji et al., 2017; Shefa and Yeo, 2017).
These amount of data prompted many researchers to deeply
investigate the pharmacological effects of this gasotransmitter as
neuromodulator, neuroprotective and anti-inflammatory agent.
The primary physiological source of H2S in the brain
is CBS, a cytoplasm Pyridoxal-5′-phosphate (PLP)-dependent
enzyme (Abe and Kimura, 1996). Noteworthy, in the brain
of Alzheimer’s disease (AD) patients has been observed a
dramatic decrease of CBS activity and a consequent severe
reduction in H2S levels (about 55%) (Eto et al., 2002a). Likewise,
endogenous H2S production was found to decrease during the
development of Parkinson disease (PD) (Kida et al., 2011).
In CNS, H2S, at physiological concentrations, acts mainly
as neuromodulator (Kimura, 2002; Zhang and Bian, 2014)
via the involvement of at least two classes of ionotropic
glutamate receptors, N-methyl-D-aspartate (NMDA) and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors, which play critical roles in synaptic plasticity (Eto et al.,
2002b; Kimura, 2002). Even if the mechanism of action need to
be further elucidated, H2S seems to acts both directly on NMDA
receptor (via sulfhydrating cysteine residues) (Kimura, 2013) and
indirectly, through the regulation of intracellular Ca+2 levels
(Nagai et al., 2004).
Further studies showed that H2S provides protection to
neurons against OS in both extracellular and intracellular
microenvironments. H2S protects the brain through the
enhancement of γ-glutamylcysteine synthetase (γ-GCS) activity
and cystine transport, which lead to an increase of intracellular
glutathione (GSH) levels (Kimura and Kimura, 2004). Another
mechanism involved in cytoprotection is the stabilization of
membrane potentials. Kimura et al. demonstrated that KATP
and Cl− (CFTR) channels are activated by H2S as protective
mechanism fromOS in an immortalized mouse hippocampal cell
line (HT22) (Kimura et al., 2006).
H2S has also been found to exert both pro- and anti-
inflammatory effects. It is now clear that microglia and
astrocytes contribute to neuroinflammatory processes through
the production of ROS and pro-inflammatory mediators.
Notwithstanding, Lee et al. showed that, in presence of H2S, this
process could be inhibited. It seems that H2S narrows the release
of pro-inflammatory factors, including tumor necrosis factor-
alpha (TNF-α), IL-1β, and nitric oxide (NO), and, at the same
time, up-regulates the production of anti-inflammatory cytokines
such as IL-4 and IL-10 (Lee et al., 2010; Huang et al., 2016).
Additionally, H2S may regulate neuroinflammation through
the inhibition of LPS-stimulated inducible NO synthase (iNOS)
and p38mitogen-activated protein kinase (p38-MAPK) signaling
pathways (Hu et al., 2007; Liu et al., 2015).
As a whole, these findings corroborate the functional
involvement of H2S in neurodegenerative diseases (He et al.,
2016; Yuan et al., 2017). Therefore, the restoration of correct
levels of endogenous H2S is an appealing challenge for the
development of new potential therapies for CNS disorders.
Although the advantages of multi-target strategy are clear,
the discovery of new multi-target drugs endowed of H2S-
releasing properties is still in its infancy, at least in the field of
neurodegenerative diseases.
A recent paper of Egea et al. (2015) described the first
multitarget compound provided of neuroprotective and
antioxidant properties. The molecule, named ITH12674
(Table 1), was synthesized through the combination of
two pharmacophore moieties belonging to sulforaphane
and melatonin. Sulforaphane is part of many members
of the Brassicaceae family, such as cabbages and broccoli,
and it showed a significant neuroprotective profile in OS
models of neurodegenerative diseases such as AD, PD, and
inflammation (Innamorato et al., 2008). The neuroprotective
effect of sulforaphane, which bears an isothiocyanate function,
is due to an Nrf2-mediated antioxidant response (Tebay
et al., 2015). Melatonin is an endogenous whose levels
decreases with aging. The neuroprotection elicited by
melatonin is mainly related to its potent antioxidant and
scavenger activity (Reiter et al., 2009). Thus, ITH12674
was obtained by the replacement of the amine-group of
melatonin with the isothiocyanate of sulforaphane. In vitro
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assays showed that ITH12674 elicited better neuroprotective
effects when compared to parent drugs (Egea et al.,
2015).
The main drawback in the administration of gaseous
H2S is the difficulty to ensure an accurate dosage thus
avoiding the risk of overdose (with dramatic consequences
due to H2S toxicity). Therefore, the development of “sulfide-
precursors” or “prodrugs” able to produce H2S as a result
of endogenous metabolism, is currently being the most
investigated strategy. Actually, medicinal chemistry is exploring
new natural (Citi et al., 2014) and synthetic (Martelli et al.,
2013; Zheng et al., 2016; Barresi et al., 2017; Zhao et al.,
2017) H2S-releasing agents as worthwhile tools for the
development of new MTDL with H2S-related pharmacological
properties.
As well as Brassicaceae, Allium sativum is another
natural source of organic sulfur-containing compounds. In
particular, S-Allylcysteine (SAC), one of the major water-
soluble transformation product from garlic, turned out to be
active in preventing the damage associated with OS (Rojas
et al., 2011) and cancer (Nicastro et al., 2015). Moreover,
it elicited cardioprotective effects in a rat model of acute
myocardial infarction (Chuah et al., 2007). However, it still
remains uncertain whether SAC acts as a H2S precursor or as
a pharmacological activator of H2S-synthesized enzymes (Guo
et al., 2013).
Recently, a structural analog of SAC, S-propargyl-cysteine
(SPRC) (ZYZ-802), has been identified as a new sulfur-
containing amino acid (Wang et al., 2009). SPRC represents
a new H2S-donor agent able to reduce deleterious effects of
OS since it showed to be able to prevent the decrease of H2S
levels in rat hippocampus subjected to lipopolysaccharide (LPS)
insult and inhibit TNF-α, TNF-α receptor 1 (TNFR1), and Aβ
generation (Gong et al., 2011).
Santos et al. explored a set of natural-based hybrids
obtained by the conjunction of SAC or SPRC moiety with
tacrine, the first cholinesterase inhibitor approved for the
treatment of AD. Among the new series of compounds
synthesized, Tacrine-SPRC (Table 1) showed to prevent Aβ-
induced toxicity and H2O2-induced OS in SH-SY5Y cells
(Keri et al., 2016). Even though Tacrine-SPRC was synthesized
aiming to develop a hybrid molecule between a native
drug and a natural antioxidant compound, SPRC could be
classified as a H2S-releasing agent, thus leading us to consider
Tacrine-SPRC as promising scaffold for the development
of new H2S-releasing/cholinesterase inhibitor drugs for AD
therapy.
CONCLUSIONS
Latest investigations focused on pleiotropic activity of
endogenous H2S led to recognize it as a key mediator implicated
in many physiological aspects in human body.
The multiple effects induced by H2S resulted from the wide
variety of targets involved. Despite the efforts, the mechanisms
of action that should clarify the pharmacological effects are
still not completely unrevealed. Nevertheless, many attempts
in exploiting the multifaceted profile of this molecule have
already been accomplished by medicinal chemists and several
chemical entities containing an H2S-releasing moiety have been
synthetized.
Herein, we focused on recent investigations on multitarget
molecules able to release H2S. A drug that potentially “hits” more
that one targets offers the possibility to increase the efficacy,
limiting at the same the potential drawbacks generally arising
from monotherapy with a single-target drug or a combination
regimen of multiple drugs. Even if a new (H2S-releasing) hybrid
could show improved PD and PK properties than “native drug,”
the main drawback for this kind of combination is to foresee a
“tissue-specific” H2S-release and thus avoiding systemic effects.
The strategy discussed here revealed that the right combination
of a “native drug” with moieties structurally able to release H2S
could improve the toxicity profile (i.e., alendronate) or ameliorate
the pharmacological effects of “old” drugs (i.e., tacrine-SPRC).
Even though this mediator has been widely investigated in
the cardiovascular field, recent efforts in the search of new
chemical structures to control H2S release are paving the way
to the exploitation of this pleiotropic gasotrasmitter in other
therapeutic fields, such as bone diseases and neurodegenerative
disorders.
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